CLDN11

Across TCGA pan-cancer cohorts, CLDN11 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of CLDN11’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CLDN11 RNA is repressed in tumor relative to normal tissue. In most cancer types CLDN11 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, COAD, and LUAD are the cancer types where CLDN11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLDN11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−1.712	<.001	11	view →
COAD	Female	All	−1.071	<.001	10	view →
LUAD	Female	III,IV	−1.741	<.001	9	view →
HNSC	Male	All	−1.288	<.001	8	view →
KICH	All	II,III,IV	−1.709	<.001	7	view →
BRCA	Female	II,III,IV	−2.521	<.001	6	view →
BLCA	Male	All	−1.985	<.001	6	view →
UCEC	All	All	−1.795	<.001	6	view →
THCA	All	All	+0.329	.003	6	view →
KIRP	Male	All	−1.485	<.001	3	view →
LUSC	All	All	−0.777	.009	3	view →
CHOL	All	All	+1.371	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

CLDN11–KIRC

Open the KIRC breakdown →